{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:41:23Z","timestamp":1793403683805,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["20224BAB206055"],"award-info":[{"award-number":["20224BAB206055"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Second Affiliated Hospital of Nanchang University, National Natural Science Foundation incubation project","award":["2021YNFY12029"],"award-info":[{"award-number":["2021YNFY12029"]}]},{"name":"CSCO-Pilotage Cancer Research Fund","award":["Y-2019AZQN-0018"],"award-info":[{"award-number":["Y-2019AZQN-0018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14109-9","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T07:25:29Z","timestamp":1744874729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Heping","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"14109_CR1","doi-asserted-by":"crossref","unstructured":"Rl HSJF. S, M L, I S, A J. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71.","DOI":"10.3322\/caac.21660"},{"key":"14109_CR2","doi-asserted-by":"publisher","first-page":"175024","DOI":"10.1016\/j.ejphar.2022.175024","volume":"926","author":"Y Li","year":"2022","unstructured":"Li Y, Youssef SF, Buanz AB. Intravesical combination therapies for non-muscle invasive bladder cancer: recent advances and future directions. Eur J Pharmacol. 2022;926:175024.","journal-title":"Eur J Pharmacol"},{"key":"14109_CR3","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314.","journal-title":"N Engl J Med"},{"key":"14109_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/cancers14010073","volume":"14","author":"AS Walia","year":"2021","unstructured":"Walia AS, Sweis RF, Agarwal PK, Kader AK, Modi PK. Cost-effectiveness of immune checkpoint inhibitors in urothelial carcinoma-a review. Cancers (Basel). 2021;14:73.","journal-title":"Cancers (Basel)"},{"key":"14109_CR5","doi-asserted-by":"publisher","first-page":"28408","DOI":"10.18632\/oncotarget.16083","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen C, Hu L, Chen Y, Hou J. The prognostic value of histological subtype in patients with metastatic bladder cancer. Oncotarget. 2017;8:28408\u201317.","journal-title":"Oncotarget"},{"key":"14109_CR6","doi-asserted-by":"crossref","unstructured":"T LD, Jl TMK, H-D JNM et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33.","DOI":"10.1038\/ng1061"},{"key":"14109_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-018-0426-4","volume":"25","author":"AZ Ayob","year":"2018","unstructured":"Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20.","journal-title":"J Biomed Sci"},{"key":"14109_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.","journal-title":"Signal Transduct Target Ther"},{"key":"14109_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MOU.0b013e32833cc9df","volume":"20","author":"KS Chan","year":"2010","unstructured":"Chan KS, Volkmer J-P, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol. 2010;20:393\u20137.","journal-title":"Curr Opin Urol"},{"key":"14109_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/cells9010235","volume":"9","author":"A Abugomaa","year":"2020","unstructured":"Abugomaa A, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging roles of cancer stem cells in bladder cancer progression, tumorigenesis, and resistance to chemotherapy: a potential therapeutic target for bladder cancer. Cells. 2020;9:235.","journal-title":"Cells"},{"key":"14109_CR11","first-page":"5782","volume":"11","author":"F Naz","year":"2021","unstructured":"Naz F, Shi M, Sajid S, Yang Z, Yu C. Cancer stem cells: a major culprit of intra-tumor heterogeneity. Am J Cancer Res. 2021;11:5782\u2013811.","journal-title":"Am J Cancer Res"},{"key":"14109_CR12","doi-asserted-by":"publisher","first-page":"950241","DOI":"10.3389\/fcell.2022.950241","volume":"10","author":"J Tan","year":"2022","unstructured":"Tan J, Wang Y, Sun L, Xu S, Li C, Jin X. The origin and evolution of bladder cancer stem cells. Front Cell Dev Biol. 2022;10:950241.","journal-title":"Front Cell Dev Biol"},{"key":"14109_CR13","unstructured":"X W, H Z, X C. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist (Alhambra Calif). 2019;2."},{"key":"14109_CR14","doi-asserted-by":"crossref","unstructured":"Hw K, Wj K, WC, Sj Y. Tumor heterogeneity in muscle-invasive bladder cancer. Translational Androl Urol. 2020;9.","DOI":"10.21037\/tau.2020.03.13"},{"key":"14109_CR15","doi-asserted-by":"publisher","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev\u00e9 ER, et al. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. Sci Transl Med. 2023;15:eabn4118.","journal-title":"Sci Transl Med"},{"key":"14109_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"14109_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"key":"14109_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173:338\u2013e35415.","journal-title":"Cell"},{"key":"14109_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13287-023-03406-4","volume":"14","author":"M Liu","year":"2023","unstructured":"Liu M, Zhou R, Zou W, Yang Z, Li Q, Chen Z, et al. Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients. Stem Cell Res Ther. 2023;14:238.","journal-title":"Stem Cell Res Ther"},{"key":"14109_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"14109_CR21","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"14109_CR22","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9:e107468.","journal-title":"PLoS ONE"},{"key":"14109_CR23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"14109_CR24","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"14109_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","volume":"11","author":"S Engebretsen","year":"2019","unstructured":"Engebretsen S, Bohlin J. Statistical predictions with Glmnet. Clin Epigenetics. 2019;11:123.","journal-title":"Clin Epigenetics"},{"key":"14109_CR26","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1038\/s41598-023-33327-4","volume":"13","author":"NS Maurya","year":"2023","unstructured":"Maurya NS, Kushwah S, Kushwaha S, Chawade A, Mani A. Prognostic model development for classification of colorectal adenocarcinoma by using machine learning model based on feature selection technique Boruta. Sci Rep. 2023;13:6413.","journal-title":"Sci Rep"},{"key":"14109_CR27","doi-asserted-by":"publisher","first-page":"14016","DOI":"10.1073\/pnas.0906549106","volume":"106","author":"KS Chan","year":"2009","unstructured":"Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009;106:14016\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14109_CR28","doi-asserted-by":"crossref","unstructured":"Y L, H T, M W, K W, Y W, N J. The potential diagnosis role of TP53 mutation in advanced bladder cancer: a meta-analysis. J Clin Lab Anal. 2021;35.","DOI":"10.1002\/jcla.23765"},{"key":"14109_CR29","doi-asserted-by":"crossref","unstructured":"G W, F W, K L, S L, C Z, C F. Significance of TP53 mutation in bladder cancer disease progression and drug selection. PeerJ. 2019;7.","DOI":"10.7717\/peerj.8261"},{"key":"14109_CR30","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.18632\/aging.102728","volume":"12","author":"G Zhu","year":"2020","unstructured":"Zhu G, Pei L, Li Y, Gou X. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging. 2020;12:2132\u201341.","journal-title":"Aging"},{"key":"14109_CR31","doi-asserted-by":"publisher","first-page":"e127901","DOI":"10.1172\/jci.insight.127901","volume":"4","author":"Q Jia","year":"2019","unstructured":"Jia Q, Wang J, He N, He J, Zhu B. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight. 2019;4:e127901.","journal-title":"JCI Insight"},{"key":"14109_CR32","doi-asserted-by":"publisher","first-page":"108924","DOI":"10.1016\/j.biopha.2019.108924","volume":"115","author":"P Sun","year":"2019","unstructured":"Sun P, Wu T, Sun X, Cui Z, Zhang H, Xia Q, et al. KMT2D inhibits the growth and metastasis of bladder cancer cells by maintaining the tumor suppressor genes. Biomed Pharmacother. 2019;115:108924.","journal-title":"Biomed Pharmacother"},{"key":"14109_CR33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/ijms24021092","volume":"24","author":"MD P\u00e9rez-Montiel","year":"2023","unstructured":"P\u00e9rez-Montiel MD, Cerrato-Izaguirre D, S\u00e1nchez-P\u00e9rez Y, Diaz-Chavez J, Cort\u00e9s-Gonz\u00e1lez CC, Rubio JA, et al. Mutational landscape of bladder cancer in Mexican patients: KMT2D mutations and chr11q15.5 amplifications are associated with muscle invasion. Int J Mol Sci. 2023;24:1092.","journal-title":"Int J Mol Sci"},{"key":"14109_CR34","doi-asserted-by":"publisher","first-page":"e0269214","DOI":"10.1371\/journal.pone.0269214","volume":"18","author":"ARAH Hamid","year":"2023","unstructured":"Hamid ARAH, Syadza YZ, Yausep OE, Christanto RBI, Muharia BHR, Mochtar CA. The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: a systematic review. PLoS ONE. 2023;18:e0269214.","journal-title":"PLoS ONE"},{"key":"14109_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13287-020-01973-4","volume":"11","author":"C Tang","year":"2020","unstructured":"Tang C, Ma J, Liu X, Liu Z. Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. Stem Cell Res Ther. 2020;11:457.","journal-title":"Stem Cell Res Ther"},{"key":"14109_CR36","doi-asserted-by":"publisher","first-page":"696716","DOI":"10.3389\/fonc.2021.696716","volume":"11","author":"J Zang","year":"2021","unstructured":"Zang J, Ye K, Fei Y, Zhang R, Chen H, Zhuang G. Immunotherapy in the treatment of urothelial bladder cancer: insights from single-cell analysis. Front Oncol. 2021;11:696716.","journal-title":"Front Oncol"},{"key":"14109_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fonc.2019.00613","volume":"9","author":"S Pan","year":"2019","unstructured":"Pan S, Zhan Y, Chen X, Wu B, Liu B. Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol. 2019;9:613.","journal-title":"Front Oncol"},{"key":"14109_CR38","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1111\/jcmm.15114","volume":"24","author":"S Kong","year":"2020","unstructured":"Kong S, Fang Y, Wang B, Cao Y, He R, Zhao Z. miR-152-5p suppresses glioma progression and tumorigenesis and potentiates Temozolomide sensitivity by targeting FBXL7. J Cell Mol Med. 2020;24:4569\u201379.","journal-title":"J Cell Mol Med"},{"key":"14109_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/jcm7100330","volume":"7","author":"H-W Chiu","year":"2018","unstructured":"Chiu H-W, Chang J-S, Lin H-Y, Lee H-H, Kuei C-H, Lin C-H, et al. FBXL7 upregulation predicts a poor prognosis and associates with a possible mechanism for paclitaxel resistance in ovarian cancer. J Clin Med. 2018;7:330.","journal-title":"J Clin Med"},{"key":"14109_CR40","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3109\/07357900902769749","volume":"27","author":"N Makrilia","year":"2009","unstructured":"Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27:1023\u201337.","journal-title":"Cancer Invest"},{"key":"14109_CR41","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/genes11080874","volume":"11","author":"Y Gu","year":"2020","unstructured":"Gu Y, Li T, Kapoor A, Major P, Tang D. Contactin 1: an important and emerging oncogenic protein promoting cancer progression and metastasis. Genes (Basel). 2020;11:874.","journal-title":"Genes (Basel)"},{"key":"14109_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-022-02377-3","volume":"41","author":"M Chi","year":"2022","unstructured":"Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K\/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41:175.","journal-title":"J Exp Clin Cancer Res"},{"key":"14109_CR43","unstructured":"B R, S E, M E, E S, L P, P K, et al. TNF-Stimulated Gene-6 Is a Key Regulator in Switching Stemness and Biological Properties of Mesenchymal Stem Cells. Stem cells (Dayton, Ohio). 2019;37."},{"key":"14109_CR44","doi-asserted-by":"publisher","first-page":"e29311","DOI":"10.1016\/j.urolonc.2018.12.009","volume":"37","author":"T-C Chan","year":"2019","unstructured":"Chan T-C, Li C-F, Ke H-L, Wei Y-C, Shiue Y-L, Li C-C, et al. High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas. Urol Oncol. 2019;37:e29311\u201324.","journal-title":"Urol Oncol"},{"key":"14109_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/vco.12884","volume":"21","author":"J-H Lee","year":"2023","unstructured":"Lee J-H, An J-H, Youn H-Y. Tumour necrosis factor stimulated gene 6 intrinsically regulates PD-L1 expressions in breast cancer cells, leading to modulation of tumour microenvironment. Vet Comp Oncol. 2023;21:255\u201369.","journal-title":"Vet Comp Oncol"},{"key":"14109_CR46","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.7150\/ijbs.69178","volume":"18","author":"B Liu","year":"2022","unstructured":"Liu B, Liu T, Liu Y, Feng X, Jiang X, Long J, et al. TSG-6 promotes cancer cell aggressiveness in a CD44-dependent manner and reprograms normal fibroblasts to create a pro-metastatic microenvironment in colorectal cancer. Int J Biol Sci. 2022;18:1677\u201394.","journal-title":"Int J Biol Sci"},{"key":"14109_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14:45.","journal-title":"J Hematol Oncol"},{"key":"14109_CR48","doi-asserted-by":"crossref","unstructured":"L M, H C, W Y, Z J. Crosstalk between mesenchymal stem cells and cancer stem cells reveals a novel stemness-related signature to predict prognosis and immunotherapy responses for bladder cancer patients. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24054760"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T07:25:36Z","timestamp":1744874736000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14109"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14109-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received approval from the ethics committee of the Second Affiliated Hospital of Nanchang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"717"}}